These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 23135382)

  • 1. Intentional low-molecular-weight heparin overdose: a case report and review.
    Byrne M; Zumberg M
    Blood Coagul Fibrinolysis; 2012 Dec; 23(8):772-4. PubMed ID: 23135382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant activated factor VII treatment of retroperitoneal hematoma in a patient with renal failure receiving enoxaparin and clopidogrel.
    Cherfan A; Arabi Y; Al Askar A; Al Shimemeri A
    Pharmacotherapy; 2007 May; 27(5):755-9. PubMed ID: 17461711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protamine reversal of low molecular weight heparin: clinically effective?
    van Veen JJ; Maclean RM; Hampton KK; Laidlaw S; Kitchen S; Toth P; Makris M
    Blood Coagul Fibrinolysis; 2011 Oct; 22(7):565-70. PubMed ID: 21959588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enoxaparin dose adjustment is associated with low incidence of venous thromboembolic events in acute burn patients.
    Lin H; Faraklas I; Saffle J; Cochran A
    J Trauma; 2011 Dec; 71(6):1557-61. PubMed ID: 22027887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal Activity and Toxicity of Heparin-Binding Copolymer after Subcutaneous Administration of Enoxaparin in Mice.
    Swieton J; Miklosz J; Yusa SI; Szczubialka K; Pawlak D; Mogielnicki A; Kalaska B
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intentional overdose with tinzaparin: management dilemmas.
    Balla I; Karafotias I; Christopoulos C
    J Emerg Med; 2014 Feb; 46(2):197-201. PubMed ID: 24084058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are low-molecular-weight heparins appropriately dosed in patients with CKD stage 3 to 5?
    Yildirim T; Kocak T; Buyukasik Y; Yilmaz R; Altun B; Erdem Y; Arici M
    Blood Coagul Fibrinolysis; 2012 Dec; 23(8):700-4. PubMed ID: 23135378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro.
    Gatt A; van Veen JJ; Woolley AM; Kitchen S; Cooper P; Makris M
    Thromb Haemost; 2008 Aug; 100(2):350-5. PubMed ID: 18690358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of recombinant factor VIIa (NovoSeven(®)) in 8 patients with ongoing life-threatening bleeding treated with fondaparinux.
    Luporsi P; Chopard R; Janin S; Racadot E; Bernard Y; Ecarnot F; Séronde MF; Briand F; Guignier A; Descotes-Genon V; Meneveau N; Schiele F
    Acute Card Care; 2011 Jun; 13(2):93-8. PubMed ID: 21517672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Massive intentional enoxaparin overdose managed with minimal protamine: A single case report.
    de Olano J; Howland MA; Su MK
    Am J Health Syst Pharm; 2023 Apr; 80(9):e98-e103. PubMed ID: 36786407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of low-molecular-weight heparin-induced bleeding in patients with pre-existing hypercoagulable states with human recombinant activated factor VII concentrate.
    Firozvi K; Deveras RA; Kessler CM
    Am J Hematol; 2006 Aug; 81(8):582-9. PubMed ID: 16823826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety and efficacy of use of low-molecular-weight heparin in pediatric neurosurgical patients.
    Gonda DD; Fridley J; Ryan SL; Briceño V; Lam SK; Luerssen TG; Jea A
    J Neurosurg Pediatr; 2015 Sep; 16(3):329-34. PubMed ID: 26067336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-Xa activity after enoxaparin prophylaxis in hospitalized patients weighing less than fifty-five kilograms.
    Rojas L; Aizman A; Ernst D; Acuña MP; Moya P; Mellado R; Cerda J
    Thromb Res; 2013; 132(6):761-4. PubMed ID: 24521789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protamine sulfate for the reversal of enoxaparin associated hemorrhage beyond 12 h.
    Lauer BR; Nelson RA; Adamski JH; Gibbons J; Janko MR; Ravi G; Barcelona RA
    Am J Emerg Med; 2019 Jan; 37(1):174.e5-174.e6. PubMed ID: 30274763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implementation of an enoxaparin protocol for venous thromboembolism prophylaxis in obese surgical intensive care unit patients.
    Ludwig KP; Simons HJ; Mone M; Barton RG; Kimball EJ
    Ann Pharmacother; 2011 Nov; 45(11):1356-62. PubMed ID: 22009998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant factor VIIa to manage major bleeding from newer parenteral anticoagulants.
    Vavra KA; Lutz MF; Smythe MA
    Ann Pharmacother; 2010 Apr; 44(4):718-26. PubMed ID: 20233918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant activated factor VII for treatment of enoxaparin-induced bleeding.
    Hu Q; Brady JO
    Mayo Clin Proc; 2004 Jun; 79(6):827. PubMed ID: 15182101
    [No Abstract]   [Full Text] [Related]  

  • 18. Neutralization of enoxaparine-induced bleeding by protamine sulfate.
    Van Ryn-McKenna J; Cai L; Ofosu FA; Hirsh J; Buchanan MR
    Thromb Haemost; 1990 Apr; 63(2):271-4. PubMed ID: 2163553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intentional overdose of warfarin in an adult: anticoagulant reversal in the ED.
    Matthews SS; Ringeisen AL; Wedro B
    Am J Emerg Med; 2014 Sep; 32(9):1150.e1-2. PubMed ID: 24674108
    [No Abstract]   [Full Text] [Related]  

  • 20. Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder.
    Yilmaz D; Karapinar B; Balkan C; Akisü M; Kavakli K
    Pediatr Hematol Oncol; 2008 Jun; 25(4):301-11. PubMed ID: 18484474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.